REGN

Regeneron Pharmaceuticals
D

REGN

702.60
USD
-5.64
(-0.80%)
Market Closed
Volume
21,899
EPS
44
Div Yield
-
P/E
17
Market Cap
77,208,384,481
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    4.190
    (2.44%)
    175.700 USD
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    JNJ
    JNJ
    0.890
    (0.62%)
    144.450 USD
    LLY
    LLY
    11.01
    (1.45%)
    768.44 USD
    MRNA
    MRNA
    -0.200
    (-0.51%)
    39.360 USD
    NVS
    NVS
    0.340
    (0.35%)
    97.070 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    More
News

Title: Regeneron Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Regeneron Pharmaceuticals Inc. is an integrated biotechnology firm. The company was founded in 1988 and is headquartered in Tarrytown, New York. It develops, manufactures and sells medicines for serious conditions such as eye diseases, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and more. Its product line includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST and ZALTRAP. The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988.